The aim of this study was to evaluate the cost-effectiveness, from a societal perspective, of the Finnish nationwide breast carcinoma screening program.
The effects were measured in life-years saved from 1987 to 2020, using data from the nationwide program to the end of 1992.
A total of 90,000 women ages 50-59 were invited for screening during the years 1987-89.
The total number of participants screened was 76,000.
The screening interval was 24 months, with follow-up to the end of 1992.
From the beginning of 1993, the estimation model used parameters based on published studies and national cancer statistics.
Data on health care and non-health care costs and time costs were obtained from internal accounts of screening units, published studies, national statistics, health market sources, and a questionnaire completed by a sample of 1400 screening attendees.
The discount rate, the annual rate of time preference over future costs and life-years saved, was 3%. The main outcome measure was the cost per life-year saved.
The estimated number of life-years of life saved was 578, of which 8% occurred 1987-1992.
The estimated life-years saved per 1000 screenings was 3.2. The total costs were $11 million in U.S. dollars, i.e., $14.3 million per 100,000 participants. (...)
Mots-clés Pascal : Carcinome, Glande mammaire, Dépistage, Mammographie, Analyse coût efficacité, Economie santé, Finlande, Europe, Homme, Tumeur maligne, Glande mammaire pathologie, Radiodiagnostic
Mots-clés Pascal anglais : Carcinoma, Mammary gland, Medical screening, Mammography, Cost efficiency analysis, Health economy, Finland, Europe, Human, Malignant tumor, Mammary gland diseases, Radiodiagnosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0419807
Code Inist : 002B20E02. Création : 22/03/2000.